Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab

Summary

Phase 0 Study of Brodalumab in patients with moderate to severe Hidradenitis Suppurativa to identify biomarkers of disease activity and clinical response.

Timeline

Start

2019-05-28

Primary completion

2020-06-01

Completion

2020-06-01

Publications

• Navrazhina K, Frew JW, Gilleaudeau P, Sullivan-Whalen M, Garcet S, Krueger JG. Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa. J Allergy Clin Immunol. 2021 Jun;147(6):2213-2224. doi: 10.1016/j.jaci.2020.12.651. Epub 2021 Feb 3.

Drugs

Indications